-
Novartis Aims for China to Be Second – Largest Market by 2024
•
Dan Brindle, head of Novartis AG’s (NYSE: NVS) China operations, recently spoke with Xinhua news service about the company’s ambitions in the Chinese market. Brindle expects China to become the multinational corporation’s “second-largest market by 2024.” This goal will be achieved through a series of new product approvals. “In the…
-
ESR Group Enters Life Sciences with Zhangjiang NEO Acquisition
•
Hong Kong-based real estate asset manager ESR Group Ltd (HKG: 1821) has made its first investment in the life sciences sector by acquiring an R & D business park in Shanghai’s Zhangjiang Hi-Tech Development Zone. The 8,940 sq. m. site, named Zhangjiang NEO, was purchased for RMB268 million (USD39.8 million).…
-
ClouDr Partners with Ipsen to Expand Diphereline’s Reach in China
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), known as “ClouDr,” has partnered with French pharmaceutical company Ipsen S.A. (Euronext: IPN; ADR: IPSEY) regarding Ipsen’s Diphereline (triptorelin), a natural gonadotropin-releasing hormone (GnRH) agonist analog. Financial details of the partnership were not disclosed. ClouDr is a one-stop chronic disease management…
-
E-Health Now Raises Funds for Oncology and Cardiovascular Digital Health Products
•
E-Health Now, a Beijing-based commercial insurance-focused health management service solutions provider, has raised an undisclosed amount of funds in a Series A++ financing round. The round was led by Borchid Capital, with participation from Tongji Fund. The proceeds will be used for the research and development of specialty digital health…
-
KingYee and XINSEC IOT Form Strategic Partnership for Smart Ward Solutions
•
Shanghai-based KingYee, a leading domestic intelligent medical technology and service provider, has entered into a strategic investment and collaboration agreement with XINSEC IOT, a medical internet of things (IoT) application specialist based in Guangdong. KingYee will invest in XINSEC, and the two companies will work together on the creation of…
-
Chongqing Pharscin’s Gabexate Mesylate Passes GQCE as First Generic in China
•
China-based Chongqing Pharscin Pharmaceutical Co., Ltd (SHE: 002907) announced that its gabexate mesylate has passed the generic quality consistency evaluation (GQCE), making it the first generic version of the drug to achieve this status in China. The drug is used to treat acute mild (edematous) pancreatitis and as adjuvant therapy…
-
Bennu Biotherapeutics Raises Over RMB100m in Angel+ Round for Global Pipeline Development
•
Shanghai-based cell therapy specialist Bennu Biotherapeutics has raised over RMB100 million (USD14.8 million) in an angel+ financing round. The round was led by INCE Capital and included contributions from Life Science Park Innovation Investment Fund and Witruth Capital. The proceeds will be used to advance the pre-clinical and clinical development…
-
Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study
•
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced that its randomized, double-blind, placebo-controlled, multi-dose escalation and dose exploration Phase II clinical study for the anti-IL-17A monoclonal antibody (mAb) SSGJ-608 in moderate to severe plaque psoriasis has reached its primary endpoint. Study DetailsThe study,…
